“Blinatumomab is excellent at eradicating MRD in a [patient with] MRD-positive [disease], regardless of which ALL it is, ...

Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in ...

Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and ...

Matulonis, MD, broke down the trial design, backbone regimen, and preclinical rationale that she believes made KEYNOTE-B96 a ...

You're absolutely correct. The more recent approvals have certainly been for mirvetuximab [soravtansine] for our patients ...

Panelists discuss which patients at first relapse make them think of CAR T-cell therapy and which make them pause, including ...

The faculty consider how they would answer a patient who is 5 years out from a single infusion in sustained MRD-negative ...

The new guidelines include 10 recommendations spanning extended molecular testing, JAK inhibitor use, anemia management, and ...

Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose ...

As radiotherapy becomes more strategically integrated around CAR T-cell therapy in multiple myeloma, clinicians face a choice ...

Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.

In a phase 1 trial of patients with platinum-sensitive high-grade ovarian cancer, a personalized neoantigen vaccine plus ...